Ephedra Litigation Could Threaten AER Preemption Provision – CRN’s Mister
This article was originally published in The Tan Sheet
Executive Summary
A court order overturning FDA's ban of ephedra could impact industry's ability to get federal preemption into a mandatory AER bill, Council for Responsible Nutrition President Steve Mister stated at the SupplySide East trade show and conference in Secaucus, N.J. May 3
You may also be interested in...
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."
GMP Cost Impact, Ephedra Suits Loom Over Supplement Industry – Israelsen
The Office of Management & Budget likely is delayed in releasing GMPs because it is grappling with issues surrounding the economic impact of the rule on small businesses, according to UNPA head Loren Israelsen
Trade Groups Make AER Legislation Wish List; Preemption Is Top Priority
Federal legislation requiring mandatory adverse event reporting for dietary supplements is both "likely" and "good" but must include preemption of state laws, trade groups asserted during a "State of the Industry" seminar Nov. 11 at SupplySide West in Las Vegas